Athira Pharma Files 8-K

TL;DR

Athira Pharma filed a routine 8-K on May 17th, mostly about exhibits.

AI Summary

Athira Pharma, Inc. filed an 8-K on May 17, 2024, reporting an event that occurred on May 3, 2024. The filing pertains to financial statements and exhibits, indicating a routine update or disclosure rather than a specific material event like an acquisition or major financial change.

Why It Matters

This filing serves as a public record of Athira Pharma's disclosures to the SEC, providing transparency for investors regarding company events and financial information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate or significant new risks.

Key Players & Entities

• Athira Pharma, Inc. (company) — Registrant
• May 3, 2024 (date) — Earliest event reported
• May 17, 2024 (date) — Date of report
• 001-39503 (company) — SEC File Number
• 45-3368487 (company) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq

Filing Documents

• atha-20240503.htm (8-K) — 45KB
• atha-ex99_1.htm (EX-99.1) — 8KB
• img247042425_0.jpg (GRAPHIC) — 18KB
• 0000950170-24-061837.txt ( ) — 196KB
• atha-20240503.xsd (EX-101.SCH) — 26KB
• atha-20240503_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On May 3, 2024, the United States District Court for the Western District of Washington (the "Court") issued an order (the "Order") providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira Pharma, Inc. (the "Company") against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al., No. 2:22-cv-497 and Houlihan v. Kawas et al., No. 2:22-cv-620, pending before the Court in accordance with the Stipulation of Settlement and Release Agreement, dated March 15, 2024 (the "Stipulation"). The proposed settlement calls for the Company to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards. The Order set a final approval hearing for Thursday, July 18, 2024, at 10:30 am. As required by the Order, the Company issued a press release providing notice of the Order, a copy of which is attached as Exhibit 99.1. The Company has also posted the (i) Zoom meeting information for the final approval hearing scheduled for July 18, 2024 at 10:30 a.m., (ii) a copy of the Stipulation, (iii) the Summary Notice of Proposed Settlement of Stockholder Derivative Action, and (iv) the Notice of Proposed Settlement of Derivative Actions, Final Approval Hearing, and Right to Appear, to the Investor Relations section of the Company's website, which can be found at http://investors.athira.com/ .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Athira Pharma, Inc. press release dated May 17, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: May 17, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR